Cargando…
Tumor regression is mediated via the induction of HER2(63-71)- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control
In the CT26/HER2 and 4T1.2/HER2 tumor models, CT26/HER2 cells form tumors that continue to grow, whereas 4T1.2/HER2 cells form tumors that eventually regress. Here, we investigated the differences in the behaviors of these two cell lines. When immune cells from 4T1.2/HER2 tumor-bearing animals were...
Autores principales: | Danishmalik, Sayyed Nilofar, Lee, Si-Hyeong, Sin, Jeong-Im |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432296/ https://www.ncbi.nlm.nih.gov/pubmed/28460461 http://dx.doi.org/10.18632/oncotarget.15816 |
Ejemplares similares
-
Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression
por: Li, Kunyu, et al.
Publicado: (2016) -
Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016) -
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019) -
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022) -
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)